EE210 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as Neoadjuvant Therapy and Continued as a Single Agent as Adjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer in Greece
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.478
https://www.valueinhealthjournal.com/article/S1098-3015(23)03608-2/fulltext
Title :
EE210 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as Neoadjuvant Therapy and Continued as a Single Agent as Adjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03608-2&doi=10.1016/j.jval.2023.09.478
First page :
Section Title :
Open access? :
No
Section Order :
12502